From: Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary
Age group (years)
Percentage screened
12-17
0%
18
32%
21
52%
24
62%
27
65%
30
66%
33
36
63%
39
61%
42
56%
45
53%
48
51%
51
50%
54
49%
57
40%
60
36%
63
66
27%
69
22%
>69